Endocrine News

On June 13, Sanofi announced that the US Food and Drug Administration (FDA) has granted accelerated approval to Tzield (teplizumab-mzwv) to delay the decline in endogenous (own) insulin production in children aged eight to 17 years recently diagnosed with stage 3 type 1 diabetes. Tzield is not effective as a disease-modifying therapy in non-autoimmune dysglycemic conditions. “We now have a novel therapy that targets the autoimmune and progressive nature of stage 3 type 1 diabetes,” said Aaron J.

While all of ENDO 2026 sessions are can’t miss events, certain ones almost always inspire certain passions among the attendees, and those are the debates! Former Endocrine Society president Stephen Hammes, MD, PhD, moderated the Endocrine Debate session “Low Testosterone in Obesity: Should We Treat or Not?” and Kelly Horvath has taken a deep dive in “To T or Not To T: Should We Treat Low Testosterone in Men with Obesity?” Joining Hammes to debate are Franck Mauvais-Jarvis, MD, PhD, professor...

Every year, thousands of endocrinologists descend on ENDO from around the world, one thing is certain: this event will be like no other. If you’ve only attended one meeting, you know that there’s no other endocrinology-focused conference quite like it. It is the only place for clinicians and researchers in the endocrinology field to get their collective batteries charged, regardless of where they are in their careers.

On June 14, Crinetics Pharmaceuticals, Inc. presented data from the open-label, Phase 2 congenital adrenal hyperplasia (CAH) adult study of investigational atumelnant, a novel, once-daily oral adrenocorticotropic hormone (ACTH) receptor antagonist candidate being developed for the treatment of classic CAH and ACTH-dependent Cushing’s syndrome.

Nanette Santoro, MD, knew she wanted to be a doctor at age 16, feeling like it was the best way to help people, something that would be good for mankind. The Endocrine Society is pleased to welcome Santoro, of the University of Colorado School of Medicine in Aurora, Colo., as its 2026 – 2027 president. She will take office in June 2026 at ENDO in Chicago, succeeding Carol Lange, PhD. Santoro has served as E.

At ENDO 2025 in San Francisco, researchers from Taiwan reported that consuming certain sweeteners found in some foods and beverages may increase the risk of early puberty in children. Aspartame, sucralose, glycyrrhizin, added sugars – all bad things, triggers especially in children with certain genetic traits. The more of these sweeteners the teens consumed, the higher their risk of developing central precocious puberty. The risk is even higher for girls.

Some subgroups of children with precocious puberty — such as older girls with slowly progressing puberty—may not need the same level of testing or treatment, according to a new Endocrine Society Clinical Practice Guideline released today.

The question might seem simple enough: Should we treat low testosterone in men with obesity? Yet the questions only accrue from here. The field remains divided not only on whether to treat it but also on how — and even on what to call it. This standoff is why an upcoming ENDO session in Chicago promises to be one of the meeting’s most spirited exchanges.

The Endocrine Society and Keystone Symposia are partnering to hold a series of joint translation scientific meetings that connect foundational (or basic) science with clinical practice across oncology, cardiometabolism, and diabetes with the aim of supporting a full bench-to-bedside and back research cycle.

The Endocrine Society (the Society) strives to foster an interdisciplinary community of those practicing, researching, and innovating in endocrinology. Industry is an important site of innovation in endocrinology, and the Society’s Corporate Liaison Board (CLB) plays a pivotal role in connecting industry and the global endocrine community. As the landscapes of science and medicine continue to evolve, these relationships are more important than ever.